SynthesisEndocrine2014
The association of SCGB3A2 polymorphisms with the risk of Graves' disease: a meta-analysis.
Synthesis in Endocrine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Emerging role of an immunomodulatory protein secretoglobin 3A2 in human diseases.Pharmacology & therapeutics · 2022Review
- Increased chemokine (C-C motif) ligand 21 expression and its correlation with osteopontin in Graves' disease.Endocrine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to assess the association of the SCGB3A2 -112G>A promoter polymorphism with Graves' disease(GD) using a meta-analysis. Relevant studies were identified using PubMed and EMBASE electronic databases. A meta-analysis of relevant studies was performed. This meta-analysis included four case-control studies, containing 6,913 GD cases (Caucasian 3904, Han 3009) and 7,185 controls(Caucasian 4155, Han 3030). The combined results showed a significant difference in genotype distribution (-112A/G) between GD and control populations (A vs. G P = 1.53 × 10(-7); GG vs. AA+AG P = 6.78 × 10(-9)). Meta-analysis was performed using a fixed-effects model. Under the dominant model (GG/AA + GA), the AA and GA genotypes were significantly associated with GD (pooled OR = 1.24, 95 % CI 1.12-1.37). When the two European studies are combined, the AA and GA genotypes were also significantly associated with GD (pooled OR = 1.29, 95 % CI 1.20-1.39). This meta-analysis suggests that SCGB3A2 polymorphism at positions -112G>A was associated with GD both in Chinese and Caucasian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.